Compound | t1/2 | CL | fu | CLu | Vd | F | Estimated A |
---|---|---|---|---|---|---|---|
h | ml/min/kg | ml/min/kg | l/kg | % | |||
7 | 1.4 | 72 | 0.01 | 7200 | 1.2 | 16 | 55 |
8 | 0.9 | 38 | 0.002 | 19000 | 2.8 | 60 | 100 |
9 | 0.9 | 36 | 0.002 | 18000 | 2.9 | 100 | 100 |
10 | 5.4 | 8.7 | 0.005 | 1740 | 4.0 | 100 | 100 |
11 | 1.7 | 34 | 0.002 | 17000 | 5.0 | 100 | 100 |
12 | 1.1 | 33 | 0.017 | 1940 | 3.0 | 56 | 70 |
13 | 0.4 | 37 | 0.011 | 3364 | 1.1 | 49 | 75 |
14 | 0.5 | 22 | 0.005 | 4400 | 0.5 | 95 | 100 |
15 | 0.6 | 42 | 0.006 | 7000 | 2.2 | 30 | 60 |
16 | 0.9 | 49 | 0.018 | 2722 | 3.8 | 8.0 | 20 |
Pharmacokinetic studies were performed in male rats after single intravenous (2 mg/kg, n = 1) and oral (10 mg/kg, n = 1) doses.
fu, function unbound in plasma; CLu, unbound systemic clearance; Vd, volume of distribution; F, bioavailability; A, absorption.